Business
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Clinical data supporting mechanism of action reinforce potential as a novel cancer treatmentBRISBANE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that an abstract highlighting data supporting the immune component of amezalpat’s purported mechanism of action has been accepted for poster presentation at the 2025 Ameri
About this update from Tempest Therapeutics, Inc.
[{"type":"image","alt":"Tempest Therapeutics","displaySize":"","headline":null,"caption":"Tempest Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":276,"url":"https://media.zenfs.com/en/globenewswire.com/2867b6171c53d10d1562509e04b23e18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1LCUwp9cQJNg7WFUm2vLrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM4NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2867b6171c53d10d1562509e04b23e18","width":300,"height":276}},"lazy":false},{"type":"text","content":"Clinical data supporting mechanism of action reinforce potential as a novel cancer treatment","length":92,"tagName":"p"},{"type":"text","content":"BRISBANE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that an abstract highlighting data supporting the immune component of amezalpat’s purported mechanism of action has been accepted for poster presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30, 2025 in Chicago, IL.","length":512,"tagName":"p"},{"type":"text","content":"Poster presentation details:","length":28,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:20%;width:20%;min-width:20%;vertical-align:top;","val":[{"type":"text","content":"Title:","length":6,"tagName":"p","attribs":{}}]},{"style":"max-width:80%;width:80%;min-width:80%;vertical-align:top;","val":[{"type":"text","content":"Amezalpat, a peroxisome proliferator-activated receptor alpha (PPARα) antagonist, inhibits suppressive macrophage development, activation and function","length":150,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Abstract Number:","length":16,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":"2171","length":4,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Date & Time:","length":16,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":"Monday, April 28, 2025, 9:00 a.m. – 12:00 p.m. CT","length":49,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-ali...